BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 17611572)

  • 1. Busulphan is safe and efficient treatment in elderly patients with essential thrombocythemia.
    Shvidel L; Sigler E; Haran M; Klepfish A; Duek A; Berrebi A; Shtalrid M
    Leukemia; 2007 Sep; 21(9):2071-2. PubMed ID: 17611572
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term and low-dose of busulfan is a safe and effective second-line treatment in elderly patients with essential thrombocythemia resistant or intolerant to hydroxyurea.
    Renso R; Aroldi A; Pioltelli P; Gambacorti-Passerini C; Elli EM
    Blood Cancer J; 2018 Jun; 8(6):56. PubMed ID: 29891835
    [No Abstract]   [Full Text] [Related]  

  • 3. Busulfan for the treatment of myeloproliferative neoplasms: the Mayo Clinic experience.
    Begna K; Abdelatif A; Schwager S; Hanson C; Pardanani A; Tefferi A
    Blood Cancer J; 2016 May; 6(5):e427. PubMed ID: 27232929
    [No Abstract]   [Full Text] [Related]  

  • 4. Bendamustine therapy associated resolution of anemia and splenomegaly in myelofibrosis.
    Tefferi A; Cerquozzi S; Liaw J
    Am J Hematol; 2016 Feb; 91(2):E6-7. PubMed ID: 26587685
    [No Abstract]   [Full Text] [Related]  

  • 5. Outdated dogma? Busulfan, seizure prophylaxis, and stem cell allografting.
    Ruiz-Argüelles GJ; Gomez-Almaguer D; Steensma DP
    Am J Hematol; 2012 Sep; 87(9):941. PubMed ID: 22674687
    [No Abstract]   [Full Text] [Related]  

  • 6. [Acute myeloid leukemia developing in the course of essential thrombocythemia].
    Fernández MC; Gardelegui I; Capote FJ; Gil JL; Muñoz JA
    Sangre (Barc); 1996 Oct; 41(5):405-6. PubMed ID: 9026932
    [No Abstract]   [Full Text] [Related]  

  • 7. The treatment of Polycythemia vera and thrombocythemia with myleran (busulphan).
    Epstein IS
    Isr J Med Sci; 1965 Jul; 1(4):797-9. PubMed ID: 5892718
    [No Abstract]   [Full Text] [Related]  

  • 8. Leukemia and myelodysplasia in patients with essential thrombocythemia treated with cytotoxic agents.
    Randi ML; Fabris F; Girolami A
    Haematologica; 1999 Nov; 84(11):1049-50. PubMed ID: 10553169
    [No Abstract]   [Full Text] [Related]  

  • 9. Is hydroxyurea leukemogenic in essential thrombocythemia?
    Tefferi A
    Blood; 1998 Aug; 92(4):1459-60; author reply 1460-1. PubMed ID: 9694740
    [No Abstract]   [Full Text] [Related]  

  • 10. [Hyperpigmentation induced by busulfan: a case with ultrastructure examination].
    Simonart T; Decaux G; Gourdin JM; Peny MO; Noel JC; Leclercq-Smekens M; De Dobbeleer G
    Ann Dermatol Venereol; 1999 May; 126(5):439-40. PubMed ID: 10434109
    [No Abstract]   [Full Text] [Related]  

  • 11. Transition of essential thrombocythemia to megakaryoblastic leukemia after long-term therapy with sequential busulfan, pipobroman and hydroxyurea.
    Sironi M; Bertola G; Lodato A; Spinelli M; Sciariada L
    Acta Haematol; 2003; 109(3):161-2. PubMed ID: 12714827
    [No Abstract]   [Full Text] [Related]  

  • 12. [Treatment of essential thrombocythemia--personal experience].
    Bieniaszewska M; Balon J; Brozek I; Limon J; Hellmann A
    Pol Arch Med Wewn; 2000; 103(3-4):179-85. PubMed ID: 11236245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Essential thrombocythemia: conventional therapy].
    Grossi A; Vannucchi AM; Longo G; Rafanelli D; Rossi Ferrini P
    Haematologica; 1991 Jun; 76 Suppl 3():368-70. PubMed ID: 1752534
    [No Abstract]   [Full Text] [Related]  

  • 14. Autologous stem cell transplantation for elderly patients with acute myeloid leukaemia conditioned with continuous infusion idarubicin and busulphan.
    Ferrara F; Palmieri S; Pedata M; Viola A; Izzo T; Criscuolo C; Mele G
    Hematol Oncol; 2009 Mar; 27(1):40-5. PubMed ID: 19206083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Choice of therapy and overall survival in patients with chronic myeloproliferative diseases].
    Rukavitsyn OA; Pop VP; Seriakov AP
    Vopr Onkol; 2004; 50(4):435-9. PubMed ID: 15605767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Autologous hematopoietic stem cell transplantation in chronic myeloid leukemia].
    Boqué C; Grañena A
    Sangre (Barc); 1998 Apr; 43(2):155-63. PubMed ID: 9656777
    [No Abstract]   [Full Text] [Related]  

  • 17. Maintenance chemotherapy with oral treosulfan following first-line treatment in patients with advanced ovarian cancer: feasibility and toxicity.
    Meden H; Wittkop Y; Kuhn W
    Anticancer Res; 1997; 17(3C):2221-3. PubMed ID: 9216692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Essential thrombocythemia: clinical and laboratory study of 6 cases].
    Grebe G; Alvo M; Lira P; Barria C; Mezzano D; Monsalve V
    Rev Med Chil; 1983 Dec; 111(12):1248-54. PubMed ID: 6687160
    [No Abstract]   [Full Text] [Related]  

  • 19. Primary thrombocythemia.
    Jamshidi K; Ansari A; Windschitl HE; Swaim WR
    Geriatrics; 1973 Jan; 28(1):121-33. PubMed ID: 4539498
    [No Abstract]   [Full Text] [Related]  

  • 20. Treosulfan in the treatment of metastatic renal cell carcinoma.
    Rigos D; Wechsel HW; Bichler KH
    Anticancer Res; 1999; 19(2C):1549-52. PubMed ID: 10365143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.